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Studies on the role of vascular endothelial growth factor (VEGF) as the most potent 
angiogenic factor in disease progression of nasopharyngeal carcinoma (NPC) remain 
limited, partly be due to the geographical distribution of the disease. However, it has 
never been reported from Indonesian population despite its common incidence. 
Therefore, we aimed to study the possible prognostic value of VEGF in Indonesian 
advanced stage NPC. 
A clinical examination, CT scan, and the tumor tissue and plasma collection were 
performed before a combined therapy, and a local control rate was reassessed every 3 
months to determine progression-free survival (PFS). Plasma VEGF-A was measured 
in 40 patients by ELISA, and VEGF and vWF expressions were examined in 30 
patients by immunohistochemistry. Survival curves were plotted based on plasma 
VEGF-A level, VEGF, and microvessel density (MVD) count indicated by vWF 
expressions vs PFS. 
The median follow up was 16 months. Patients with high VEGF-A level (≥834pg/ml) 
presented shorter survival rate, as compared to those of low level (<834pg/ml) (41.2% 
vs 82.6%; p=0.009, log rank 6.81). Patients with overexpressed VEGF (≥25%) showed 
shorter survival than those with low expression (<25%) (45.5% vs 79.6%; p=0.05, log 
rank 3.84). Patients with higher MVD count (≥25%) also had shorter survival than 
those with lower MVD count (53.4% vs 80%; p=0.101, log rank=2.70). 
In conclusion, an elevated plasma VEGF level predicts shorter survival for 
Indonesian advanced stage NPC in this study. However, more samples may be required 
to draw a better conclusion on a possible role of VEGF as a prognostic factor in the 
disease progression of NPC.  This data is also substantial for the development of 
anti-VEGF as a possible targeted therapy for NPC.  
 
Nasopharyngeal carcinoma (NPC) is a malignancy originating from nasopharyngeal 
epithelial cells. This disease is pathologically, epidemiologically and clinically distinct from 
other head and neck cancers. Endemic areas include Southern China, Alaska and Southeast 
Asia. There are estimated to be 10,000 new cases per year in Indonesia. It was also the most 
common malignancy in males visiting Tulip Integrated Cancer Unit of Sardjito Hospital 
Yogyakarta, Indonesia between 2001─2005, among whom 80% were diagnosed at an 
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advanced stage and who mostly had type III WHO pathological classification, which has a 
strong correlation with Epstein-Barr virus (EBV) latent infection.1 
Angiogenesis is a fundamental process in tumor growth and metastasis, the degree of 
which depends on the net balance of the effects of proangiogenic and antiangiogenic factors. 
Vascular endothelial growth factor (VEGF), widely known as vascular permeability factor 
(VPF) or vasculotropin, is a glycoprotein possessing potent angiogenic and mitogenic as well 
as increasing vascular permeability activity specific to endothelial cells.2  VEGF-A is a 
45-kDa homodimeric glycoprotein with a diverse range of angiogenic activities. The 
VEGF-A gene undergoes alternative splicing to yield mature isoforms of 121, 165, 189, and 
206 amino acids. In addition, some less commonly expressed variants have also been 
identified (VEGF145 and VEGF183). VEGF121 is freely secreted, whereas the largest 
isoforms (VEGF189 and VEGF206) are sequestered in the extracellular matrix (ECM) and 
require cleavage by proteases for their activation. VEGF165 exists in both a soluble and an 
ECM-bound form. The ECM-bound isoforms of VEGF-A, VEGF-C, and VEGF-D can be 
released in a diffusible form by plasmin cleavage at the C-terminus, which generates a 
bioactive fragment. Alternatively, VEGF can be released from the ECM by MMP-9 to 
initiate the angiogenic switch. VEGF165- which is a mature isoform of VEGF-A - is the 
predominant isoform and is commonly overexpressed in a variety of human solid tumors.2 
Data on the possible role of VEGF in head and neck cancer, including NPC, are lacking 
when compared to other malignancies, and the prognostic value of circulating VEGF and 
VEGFR expressions is not yet clear. A study from China showed elevated circulating VEGF 
in male patients with metastatic NPC; however these levels did not correlate with the 
locoregional progression of NPC, and the usefulness of detecting serum-VEGF in the early 
diagnosis of NPC appeared to be limited.3 A study from India reported a correlation between 
circulating VEGF and disease reccurence.4  
Polymorphisms of LMP-1, LMP-2 and EBNA genes of EBV have been reported in 
different ethnicities, and strongly suggest different patterns of infection that induce NPC.5  
These variations may also affect the various patterns of VEGF expression among different 
ethnicities.  
In the current study, we aimed to determine the level of plasma VEGF-A, expression of 
VEGF and microvessel density (MVD) by von Willebrand Factor (vWF) in tumor biopsy 
specimens of advanced stage NPC in the Indonesian population, and to study their 
correlations with the disease outcome. The results will contribute to further consideration and 
research into VEGF development as a targeted therapy for solid tumors, particularly NPC.  
 
MATERIALS AND METHODS 
Materials 
Patients admitted to the Tulip Integrated Cancer Unit of Sardjito Hospital Yogyakarta, 
Indonesia between January 2001 to December 2005, with biopsy-proven NPC in stage III 
and IV according to the American Joint Committee on Cancer (AJCC) VI staging system, 
were eligible for this study.6 Patients had no history of previous radiotherapy or 
chemotherapy. Other eligibility criteria were Karnofsky performance status ≥ 60%; Hb level 
≥ 10g/dl, WBC count of greater than 4x109/L and platelet count of greater than 100x109 /L; 
serum creatinine level less than 1.5 mg/dL; liver function with AST/ALT < 5 x upper limit, 
and total bilirubin less than 2.5mg/dL.  
This study was performed after approval from the institutional ethics committee. All 
patients were required to provide written informed consent before starting treatment.  
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All patients underwent fibreoptic nasopharyngoscopy and biopsy to obtain specimens for 
pathologic diagnosis. Pre-treatment staging evaluations included clinical examination of the 
head and neck; computed tomography (CT) scan or magnetic resonance imaging (MRI) from 
the skull base to the whole neck; chest radiography; whole-body bone scan; abdominal 
sonography; complete blood count with differential count, platelet count, and biochemical 
profile.  
Locally advanced disease patients received combination therapy of neo-adjuvant 
chemotherapy and radiotherapy. The chemotherapy regimen consisted of Cisplatin 
100mg/m2 day 1 and 5FU 1000mg/m2 day 1─5, with a 21-days cycle given 3 times. Four 
weeks after the last chemotherapy, external beam radiotherapy 70Gy was given to the local 
lesion followed by 20Gy of brachytherapy.7 Metastatic disease patients were treated with 
platinum-based chemotherapy. 
 All patients were subjected to physical examination, complete blood count, and platelet 
count during each week of therapy. After completion of treatment, patients were followed 
weekly until acute side effects resolved. Patients were then evaluated every 3 months with 
clinical examination, CT scan, chest radiography, abdominal sonography, blood count, and 
biochemistry tests. Tumor response with regard to disease outcome was assessed based on 
WHO criteria.8 Median of follow up duration for survival analysis was 16 months. Patients 
Progression free survival (PFS) duration was determined from informed consent until disease 
progression defined clinically, pathologically or by imaging, and death due to any cause.  
Control group included 20 normal individuals who did not have any chronic illness, since 
it may cause the pathologic elevation in any angiogenic factors.3 
Methods 
Determination of plasma VEGF-A level   
   Peripheral venous blood samples were drawn from each subject and collected in sterile 
test tubes, centrifuged at 2,000 g for 10 min and stored at -20°C until assayed collectively for 
the VEGF-A level. Plasma VEGF-A concentration was determined as plasma 
immunoreactivity by quantitative sandwich enzyme-linked immunosorbent assay (ELISA) 
(Quantikine DVE00, R&D Systems, Minneapolis, USA) recognizing VEGF-A 165bp 
splicing variant, according to the manufacturer's instructions as described previously.9 The 
assay has been reported to recognize both natural and recombinant human VEGF and not to 
exhibit cross reactivity with a series of growth factors and cytokines. The manufacturer 
claims a sensitivity of 9.0pg/mL-1. Each assay well measured 100μl plasma. All analyses and 
calibrations were carried out in duplicate. Optical density was determined using a 
microtitreplate reader at 450 nm/540nm and concentrations are given in pg/ml. 
VEGF and vWF expression 
Immunohistochemistry for VEGF and vWF from tumor biopsies was performed by a 
streptavidin biotin complex procedure. When the biopsies contained a substantial area of 
necrosis, it was excluded from the study. Endogenous peroxidase activity was blocked with 
0.3% hydrogen peroxide in methanol for 10 min at room temperature. The sections were then 
incubated with 10% normal sheep plasma in phosphate-buffered saline (PBS) solution for 30 
min, followed by overnight incubation at 4°C with rabbit anti-human VEGF polyclonal 
antibody (Thermo Scientific #RB-9031-P, California, US), specifically recognizing 165, 189 
and 121 amino acid splice variants of VEGF of human. This antibody was diluted 1:50. We 
used an antibody against VEGF other than to VEGFR in order to compare the result of the 
measurement of VEGF level of expression in the plasma and on the tissue, since these 
variants are found both in soluble and an extra cellular matrix-bound form.2 Next, each slide 
was treated with biotinylated anti-rabbit immunoglobulin for 10 min, and then incubated 
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with streptavidin-peroxidase complex for 45 min. Aminoethylnorbazole (AEC) was used as a 
chromogen, and nuclear counterstaining was performed with Mayer's hematoxylin solution. 
VEGF expression was evaluated by counting the mean number of cells stained in 5 views of 
400x magnification including 100 cells perview. Data is presented in percentage, and mean 
of ≥ 25% was defined as overexpression. The expression of von Willebrand factor (vWF) 
indicating microvessel density was assessed using in a similar method by a mouse 
anti-human vWF monoclonal antibody (clone 36B11, Novocastra Laboratories, Newcastle, 
UK), which was also diluted 1:50. Microvessels density was counted as mean number of 
cells stained within 5 views of 100x magnification, and mean number of ≥ 25 was defined as 
higher count of MVD. Immunohistochemical staining was assessed by an investigator 
without knowledge of the clinicopathological findings of the patients studied. 
Immunoreactivity of VEGF expression was evaluated semi-quantitatively using the 
following grading range: samples with low staining <25% were graded ‘+’, samples with 
medium staining between 25-50% were graded ‘++’ and samples with strong staining >50% 
were graded as ‘+++’, as previously described.9 
Statistical analysis  
   Data was analyzed using SPSS11.5 software. Kaplan-Meier analysis and logrank test 
were used to assess survival rate and to compare the difference of survival rate. Survival 
curves were then plotted based on plasma VEGF-A level, VEGF, and microvessel density 
(MVD) count indicated by vWF expressions vs PFS. 
 
RESULTS 
Patient characteristics 
Characteristics of the patients are shown in Table I. The median age was 46 years; with 
mean of age was 45.5 years, with male predomination (82.5%). WHO classification of type 3 
was mostly found (82.5%), while most of the patients were in the stage of locally advanced 
(87.5%). The median follow up for the patients was 16 months. 
 
 
Table I. Patient Characteristics 
Characteristic Number (%) 
Age, years 
   Range 
   Median 
   Mean 
 
15─67 
46 
45.5 
 Sex 
    Male 
    Female 
 
33 (82.5) 
  7 (17.5) 
WHO classification 
    Type 1 
    Type 2 
    Type 3 
 
0   (0) 
7  (17.5) 
33 (82.5) 
Stage AJCC VI 
     Locally advanced disease 
     Metastatic disease 
 
35 (87.5) 
  5 (12.5) 
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Plasma VEGF-A level 
The level of plasma VEGF in 40 patients was 821.88±353pg/ml, while the control group, 
including 20 control subjects, was 541±341.24pg/ml. To study the effectiveness of the 
plasma VEGF level in predicting disease progression, a four-fold table was used  to 
calculate the sensitivity, specificity, positive predictive value, and negative predictive value 
of plasma VEGF-A at the level of 834 pg/mL. At this level, the sensitivity was 71.3%, 
specificity was 73.1%, the positive predictive value was 58.8%, and the negative predictive 
value was 82.6%.  
The Kaplan-Meier curve showed that in group of high VEGF-A level (≥834pg/ml) 
(n=17), progression occurs in 10 patients and not in the other 7 patients (41.2%). While in 
group of low VEGF-A level (<834pg/ml) (n=23), progression was found only in 4 patients 
and not in the other 19 patients (81.26%). The difference of survival rate between the 2 
groups was significant (41.2% vs 81.26%; p=0.009, log rank=6.81) (Figure 1).   
 
 
Figure 1.  The Kaplan-Meier curve showed that in group of high VEGF-A level (≥834pg/ml) (n=17), 
progression occurs in 10 patients and not in the other 7 patients (41.2%). While in group of 
low VEGF-A level (<834pg/ml) (n=23), progression was found only in 4 patients and not 
in the other 19 patients (81.26%). The difference of survival rate between the 2 groups was 
significant (41.2% vs 81.26%; p=0.009, log rank=6.81).  
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Expression of VEGF and vWF from tumor tissue 
The levels of VEGF and vWF expression were determined in 30 patients. In group of 
patients with over expressed VEGF(≥25%) (n=11), progression occurred in 6 patients and 
not in the other 5 patients (45.5%). While in group of low VEGF expression(<25%) (n=19), 
progression was found only in 4 patients and not in the other 15 patients (79.6%). Although 
there was a trend of shorter survival rate in group of VEGF over-expression than in low 
expression one, the difference between the 2 groups was not significant (45.5% vs 79.6%; 
p=0.05, log rank 3.84) (Figure 2).   
 
 
Figure 2. Kaplan-Meier curve showing that in group of patients with over expressed VEGF  (≥25%) 
(n=11), progression occurred in 6 patients and not in the other 5 patients (45.5%). While in 
group of low VEGF expression(<25%) (n=19), progression was found only in 4 patients and 
not in the other 15 patients (79.6%). Although there was a trend of shorter survival rate in 
group of VEGF over-expression than in low expression one, the difference between the 2 
groups was not significant (45.5% vs 79.6%; p=0.05, log rank 3.84).  
 
In fifteen patients having vWF overexpression or higher MVD count (≥25), progression 
occurred in 7 patients and not in the other 8 patients (53.4%). While in group of low vWF 
expression or lower MVD count (n=15), progression was noted only in 3 and not in the other 
12 patients (80%). Although there was also a trend of shorter survival rate in group of more 
MVD count than in lower one, the difference between the 2 groups was not significant 
(53.4% vs 80%; p=0.101, log rank=2.70) (Figure 3). 
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Figure 3. Kaplan-Meier curve showing that in fifteen patients having vWF overexpression or higher 
MVD count (≥25), progression occurred in 7 patients and not in the other 8 patients (53.4%). 
While in group of low vWF expression or lower MVD count (n=15), progression was noted 
only in 3 and not in the other 12 patients (80%). Although there was also a trend of shorter 
survival rate in group of more MVD count than in lower one, the difference between the 2 
groups was not significant (53.4% vs 80%; p=0.101, log rank=2.70). 
 
DISCUSSION  
VEGF is a soluble peptide secreted by tumors into various body fluids. The finding of 
significantly higher serum VEGF levels in cancer patients than in normal subjects was firstly 
reported by Kondo et al in 1994, and was verified in subsequent studies of patients with 
various types of cancer. In the latter study, a significant correlation of the serum VEGF level 
with tumor stage, microvessel density, and tumor VEGF expression was noted. A further 
study also demonstrated a higher serum VEGF level in disseminated disease than in localized 
disease among patients with a variety of cancers, irrespective of the histologic type.8,10  
Elevation of serum-VEGF levels has been reported to be correlated with poor disease-free 
survival and poor progression-free survival in patients with urothelial carcinoma, with 
unfavorable survival in patients with small-cell lung carcinoma, with a poor 5-year survival 
rate in patients with non-Hodgkin lymphoma, and with an advanced tumor stage in patients 
with colorectal carcinoma; however, data on the role of VEGF in the disease progression of 
NPC are still lacking compared to other malignancies.11 
In this study, we found a significant difference in survival rate between patients with an 
elevated level of VEGF plasma and a low level of VEGF plasma. Such a study which 
correlates the level of plasma VEGF and disease outcome in NPC is the novel finding of this 
study, which has not been reported previously from the Indonesian population to the best of 
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our knowledge. This result is relevant to other studies on the correlation of the VEGF level 
with disease progression and patient survival in other solid tumors. Qian et al reported an 
increase in the level of serum VEGF in non-metastatic NPC compared to the normal control, 
although the difference was not significant. They also reported a significant increase in the 
level of serum VEGF in metastatic NPC compared with normal controls and non-metastatic 
NPC.3  Furthermore, the significant difference in disease progression between patients with 
an elevated and low level of plasma VEGF patients in this study possibly supported the 
theory of tumor hinderance by cytotoxic agents and the reduction of tumor oxygenation 
required for effective radiotherapy, which is caused by interstitial hypertension and poor 
blood flow, causing hypoxic and acidic microenvironments within tumors with excessive 
proliferation of endothelial cells and abnormal vessel maturation.12,13 
VEGF expression on tumor tissue is affected by several factors such as tissue hypoxia, 
growth factors and cytokines, oncogenes and tumor suppressor genes. These factors may 
contribute to variations in the results of studies on the expression of angiogenic factors on 
tumor tissues. VEGF expression is found to be highest in hypoxic regions of the tumor near 
necrotic areas; hence, the site of tumor tissue may have a profound influence on the results 
when evaluating VEGF expression in a certain tumor. The level of circulating VEGF in 
serum is related with the higher expression of VEGF receptors on tumor tissue as well as 
microvessel density, which shows the important role of VEGF in the angiogenesis process of 
tumor growth.13  In this study, we found a shorter survival in patients with overexpressed 
VEGF or vWF on tumor tissues, than in patients with a lower expression of the two markers. 
Although the differences were not significant, the trends were still obvious, as seen from the 
survival curves. These results supported the importance of VEGF and MVD examinations in 
angiogenesis, which affects tumor growth. Our biased results might be caused by the small 
sample size for tumor tissues. 
In summary, elevation in the level of plasma VEGF which correlated with shorter 
survival in Indonesian advanced stage NPC subjects in this study lends weight to the positive 
role of VEGF in the disease progression of NPC. Although conducted in small size of 
samples, we believed that these results are substantial for the future development of VEGF as 
a prognostic factor and targeted therapy for NPC through inhibition of the VEGF-mediated 
signaling pathway. Investigation with larger samples is required to draw a more precise 
conclusion on the prognostic value of VEGF in NPC. Further studies to understand the role 
of Epstein Barr virus in the disease progression of NPC through VEGF-mediated 
angiogenesis are also needed.  
 
ACKNOWLEDGEMENTS 
We would like to thank Litbangkes and Eijkman Institute Indonesia for the excellent 
technical and analysis consultations. This study was supported by a grant from 
RISBINIPTEKDOK 2006 No HK.06.01/1/916/2007. We also thank our Japanese associate, 
Professor Eiji Tatsumi, M.D., PhD, to have read our manuscript critically.  
 
 
 
 
 
 
 
 
J. KURNIANDA  et al. 
E44 
REFERENCES 
1. Hariwiyanto, B., Fachiroh, J., Paramita, D.K., Astuti, I., Harijadi, and Soeripto. 
2002. EBV-NPC in Indonesia: epidemiology and screening. 10th International 
Symposium of Epstein-Barr virus associated Malignancies, Cairns, Australia.  
2. Ferrara, N., Gerber, H.P., and LeCouter, J. 2003. The biology of VEGF and its 
receptors. Nat Med 9:669-76. 
3. Qian, C.N., Zhang, C.Q., Guo, X., Hong, M.H., Cao, S.M., and Mai W.Y. 2000. 
Elevation of serum vascular endothelial growth factor in male patients with metastatic 
nasopharyngeal carcinoma. Cancer 88(2):255-61.  
4. Krishna, S.M., James, S., and Balaram, P. 2006. Expression of VEGF as 
prognosticator in primary nasopharyngeal cancer and its relation to EBV status. Virus 
Res 115(1):85-90 
5. Burrows,J.M., Bromham ,L., Woolfit, M., Piganeau, G., Tellam, J., and Geoff, C.G. 
2004. Selection Pressure-Driven Evolution of the Epstein-Barr Virus-Encoded 
Oncogene LMP1 in Virus Isolates from Southeast Asia. J Virol 78(13): 7131–7137.  
6. Greene, F.L., Page, D.L., Fleming, I.D., Fritz, A., Balch, C.M., and Haller, D.G.  
2002. AJCC cancer staging handbook: TNM classification of malignant tumors, 6th 
ed.,Springer, New York. 
7. Levendag, P.C., Nowak, P.J., van der Sangen, M.J., Jansen, P.P., Eijkenboom, 
W.M., and Planting, A.S. 1996. Local tumor control in radiation therapy of cancers in 
the head and neck. Am J Clin Oncol 19(5):469-477. 
8. Miller, A.B, Hoogstraten, B., Staquet, M., and Winkler, A. 1981. Reporting results of 
cancer treatment. Cancer 47 : 207 – 214.  
9. Sadick, H., Naim, R., Gossler, U., Horman, K., and Riedel, F. 2005. Angiogenesis in 
hereditary hemorrhagic teleangiectasia:VEGF165 plasma concentration in correlation to 
the VEGF expression and microvessel density. Int J Mol Med 15:15-9. 
10. Kondo, S., Asano, M., Matsuo, K., Ohmori, I., and Suzuki, H. 1994.Vascular 
endothelial growth factor/vascular permeability factor is detectable in the sera of 
tumor-bearing mice and cancer patients. Biochim Biophys Acta 1221:211-214. 
11. Poon, R.T., Tat-Fan, S., and Wong, J. 2001. Clinical Implications of Circulating 
Angiogenic Factors in Cancer Patients. J Clin Oncol 19(4):1207-25.  
12. Jain, R.K. 1994. Barriers to drug delivery in solid tumors. Sci Am 271:58-65. 
13. Hicklin,D.J., and Ellis, L.M. 2005. Role of the vascular endothelial growth factor 
pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011-27. 
 
